Efficacy and Safety of Extended-Release Clonidine Hydrochloride for Attention Deficit Hyperactivity Disorder in Chinese Children and Adolescents: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Journal of Child and Adolescent Psychopharmacology · 2026
DOI: 10.1177/10445463261437785 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2026. Verfasst von Yun Qian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Adrenergic alpha-2 Receptor Agonists, Attention Deficit Disorder with Hyperactivity, Clonidine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition in children and adolescents, yet randomized controlled trial evidence supporting pharmacological treatment in Chinese populations remains limited. This study evaluated the efficacy and safety of clonidine hydrochloride extended-release tablets (CLON-XR) as monotherapies for ADHD among Chinese children and adolescents. Materials and Methods: In this 6-week, multicenter, randomized, double-blind, placebo-controlled phase 3 trial, 75 patients aged 6–17 years with ADHD were assigned (2:1) to receive once-daily CLON-XR (target dosage 0.2 mg/day) or placebo. The primary endpoint was the change from baseline to week 5 in the Swanson, Nolan, and Pelham Version-IV (SNAP-IV) total score. Secondary endpoints included SNAP-IV subscales, Clinical Global Impression—Severity (CGI-S) and Improvement (CGI-I) scores, and safety assessments.
Results
Compared with placebo, CLON-XR significantly improved the primary endpoint (least squares mean change in the SNAP-IV total score: −17.5 vs. −10.3; p = 0.0039). Significant improvements were also observed in the SNAP-IV inattention and hyperactivity/impulsivity subscales, CGI-S, and CGI-I (all p < 0.05). The incidence of treatment-emergent adverse events (TEAEs) in the CLON-XR group was comparable with that in the placebo group; the TEAEs were mild, and the dropout rate was low (5.3%). No serious adverse events or clinically significant vital sign abnormalities were reported.
Conclusions
CLON-XR was efficacious and well tolerated in Chinese children and adolescents with ADHD, supporting its potential as a nonstimulant treatment option in this population. These findings provide evidence for ADHD management in China and suggest that further investigations in longer-term and real-world settings are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Child Mental Health Research Center, Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China.
- Department of Neurology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Behavioral Development, Guangzhou Women and Children's Medical Center, Guangzhou, China.
- Child and Adolescent Psychology Department, Xiamen Xianyue Hospital, Xianyue Hospital Affiliated with Xiamen Medical College, Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen, Chin…
- Department of Pediatrics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zitieren
APA
Qian, Y., Ke, X., Gao, F., Chen, W., Wu, W., Li, Y., Du, L., Li, H., & Du, Y. (2026). Efficacy and Safety of Extended-Release Clonidine Hydrochloride for Attention Deficit Hyperactivity Disorder in Chinese Children and Adolescents: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1177/10445463261437785
Vancouver
Qian Y, Ke X, Gao F, Chen W, Wu W, Li Y, et al. Efficacy and Safety of Extended-Release Clonidine Hydrochloride for Attention Deficit Hyperactivity Disorder in Chinese Children and Adolescents: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. 2026. doi:10.1177/10445463261437785
BibTeX
@article{Qian2026,
author = {Qian, Yun and Ke, Xiaoyan and Gao, Feng and Chen, Wenxiong and Wu, Weige and Li, Yaping and Du, Lijun and Li, Huafang and Du, Yasong},
title = {Efficacy and Safety of Extended-Release Clonidine Hydrochloride for Attention Deficit Hyperactivity Disorder in Chinese Children and Adolescents: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2026},
doi = {10.1177/10445463261437785}
}
EUVIMED